Ionis director sells shares after option exercises
Ionis Pharmaceuticals director Joseph Loscalzo reported paired option exercises and stock sales on May 4, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ionis Pharmaceuticals director Joseph Loscalzo reported paired option exercises and stock sales on May 4, 2026. He sold a total of 77,289 shares of Common Stock in open-market transactions at weighted average prices of $75.58 and $74.90, under a pre-arranged Rule 10b5-1 Trading Plan adopted on November 18, 2025. To fund these sales, he exercised non-qualified stock options covering 77,289 shares at exercise prices between $38.06 and $64.80. Following the transactions, he continued to hold more than 36,000 shares of Ionis stock directly.
Insider Trade Summary 10b5-1
Exercise and Sale: 77,289 shares ($2.03M approx. pre-tax spread)
Exercise and Sale
14 txns
Insider
LOSCALZO JOSEPH
Role
Director
Sold
77,289 shs ($5.80M)
Approx. gross sale proceeds
$5.80M
Approx. exercise cost
$3.77M
Approx. pre-tax spread
$2.03M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 10,968 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) | 12,000 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) | 10,321 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) | 16,000 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) | 12,000 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) | 16,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,968 | $38.06 | $417K |
| Exercise | Common Stock | 12,000 | $40.05 | $481K |
| Exercise | Common Stock | 10,321 | $41.08 | $424K |
| Exercise | Common Stock | 16,000 | $42.88 | $686K |
| Exercise | Common Stock | 12,000 | $60.20 | $722K |
| Exercise | Common Stock | 16,000 | $64.80 | $1.04M |
| Sale | Common Stock | 59,508 | $74.9024 | $4.46M |
| Sale | Common Stock | 17,781 | $75.5826 | $1.34M |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 36,330 shares (Direct)
Footnotes (3)
- F1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 18, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.49 to $75.49 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.495 to $75.98 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Key Figures
Shares sold: 77,289 shares
Weighted avg sale price 1: $75.5826 per share
Weighted avg sale price 2: $74.9024 per share
+5 more
8 metrics
Shares sold
77,289 shares
Total common shares sold on May 4, 2026
Weighted avg sale price 1
$75.5826 per share
First open-market sale tranche on May 4, 2026
Weighted avg sale price 2
$74.9024 per share
Second open-market sale tranche on May 4, 2026
Shares underlying options exercised
77,289 shares
Non-qualified stock options exercised into common stock
Option exercise prices
$38.06–$64.80 per share
Strike price range for exercised non-qualified options
Net buy/sell shares
−77,289 shares
Net share change from all reported transactions
Post-transaction direct holdings (minimum)
>36,000 shares
Minimum direct common shares held after transactions
10b5-1 plan adoption date
November 18, 2025
Date Loscalzo adopted trading plan used for these sales
Key Terms
Rule 10b5-1 Trading Plan, Non-Qualified Stock Option (right to buy), weighted average price, derivative security, +1 more
5 terms
Rule 10b5-1 Trading Plan regulatory
"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option (right to buy) financial
"security_title: Non-Qualified Stock Option (right to buy)"
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Ionis Pharmaceuticals (IONS) director Joseph Loscalzo report on this Form 4?
He reported exercising non-qualified stock options and selling 77,289 shares of Ionis Pharmaceuticals common stock. The transactions occurred on May 4, 2026, and were conducted as open-market sales paired with option exercises.
What stock options did Loscalzo exercise in connection with these Ionis (IONS) trades?
He exercised non-qualified stock options covering 77,289 underlying shares of common stock. The options had exercise prices between $38.06 and $64.80, with original exercise dates from 2019 through 2024 and expirations out to 2033.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates